# US 2026/0028674 A1 · Biomarker-based treatment and diagnostic methods for il-17-dependent conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028674 A1
- Document ID: US20260028674A1
- Status: Published application
- Kind: A1
- Application number: 19/122,557
- Filed: 2024-04-18
- Published: 2026-01-29
- Earliest claimed: 2023-04-18
- Assignees: Moonlake Immunotherapeutics AG
- Applicants: Moonlake Immunotherapeutics AG
- Inventors: Kristian REICH; Eva CULLEN; Sara Raquel SOUTO PEREIRA; Alex GODWOOD; Jorge SANTOS DA SILVA
- Web page: https://patentgrep.com/patent/US20260028674A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/10: Anti-acne agents
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6869: {Interleukin}
- G01N 33/6881: {from skin}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/522: Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
- G01N 2333/523: Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
- G01N 2333/54: Interleukins [IL]
- G01N 2333/5412: IL-6
- G01N 2333/545: IL-1
- G01N 2333/55: IL-2
- G01N 2800/20: Dermatological disorders
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

## Claims

### Claim at position 1

-65. (canceled)

### Claim 66

A kit for identifying a subject at risk or in need of treatment for an IL-17-dependent condition, which kit comprises a reagent or reagents for measuring the level or expression of one or more of: IL6, PLA2G2A, IL19, PI3, CST7, IL 17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, ILIRL2, RCOR1, and EDAR.

### Claim 67 (depends on 66)

The kit of claim 66, which comprises packaged components for obtaining a biological sample from a subject.

### Claim 68 (depends on 67)

The kit of claim 67, which comprises components for obtaining a skin sample or a biological fluid sample.

### Claim 69 (depends on 68)

The kit of claim 68, which comprises an adhesive strip for obtaining a skin sample.

### Claim 70 (depends on 67)

The kit of claim 67, which comprises components for obtaining a punch biopsy, microbiopsy, or surgical specimen.

### Claim 71

A kit for treating an IL-17-dependent dermatological condition, wherein the kit comprises a pharmaceutical composition comprising an inhibitor of IL-17A and/or IL-17F, and a reagent for measuring the level or expression of IL6, PLA2G2A, IL19, PI3, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, ILSRA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM23, THOP1, ILIRL2, RCOR1, and/or EDAR, in a sample taken from a subject.

### Claim 72 (depends on 71)

The kit of claim 71, which comprises packaged components for obtaining a biological sample from a subject.

### Claim 73 (depends on 72)

The kit of claim 72, which comprises components for obtaining a skin sample or a biological fluid sample.

### Claim 74 (depends on 73)

The kit of claim 73, which comprises an adhesive strip for obtaining a skin sample.

### Claim 75 (depends on 72)

The kit of claim 72, which comprises components for obtaining a punch biopsy, microbiopsy, or surgical specimen.
